To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Patent number: 10585101
    Abstract: Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 10, 2020
    Assignee: WAVESENSE, INC.
    Inventor: Christopher Feistel
  • Patent number: 10488410
    Abstract: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogs, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising [antigenic molecule of first source]-[analyte auto antibody]-[antigenic molecule of second source]. The antigenic molecule of first source is immobilized to a solid phase, the second is labelled.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 26, 2019
    Assignee: RSR LIMITED
    Inventors: Bernard Rees Smith, Jadwiga Furmaniak, Michael Powell
  • Patent number: 10481156
    Abstract: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogs, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising [antigenic molecule of first source]-[analyte auto antibody]-[antigenic molecule of second source]. The antigenic molecule of first source is immobilized to a solid phase, the second is labeled.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 19, 2019
    Assignee: RSR LIMITED
    Inventors: Bernard Rees Smith, Jadwiga Furmaniak, Michael Powell
  • Patent number: 10280199
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Patent number: 10281480
    Abstract: The present invention is in the field of coagulation diagnostics and relates to methods for detecting modulators of GPIb-thrombin interaction in a sample. To this end, the sample is contacted with isolated mutated GPIb? protein and thrombin, and the formation of a complex between mutated GPIb? protein and thrombin is determined.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 7, 2019
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventor: Juergen Patzke
  • Patent number: 10214758
    Abstract: A method of digesting a lignocellulosic material is disclosed. In one embodiment, the method comprises the step of exposing the material to an effective amount of Streptomyces sp. ActE secretome such that at least partial lignocellulosic digestion occurs.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: February 26, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Brian Grant Fox, Taichi Takasuka, Adam Joel Book, Cameron Robert Currie
  • Patent number: 10202466
    Abstract: Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 12, 2019
    Assignee: CARNEGIE MELLON UNIVERSITY
    Inventor: Peter B. Berget
  • Patent number: 10191066
    Abstract: The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: January 29, 2019
    Assignee: HYTEST LTD.
    Inventors: Alexey G. Katrukha, Alexander B. Postnikov, Tatiana I. Smolyanova, Alexey V. Kharitonov, Natalia N. Tamm
  • Patent number: 10124047
    Abstract: Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: November 13, 2018
    Assignee: KODE BIOTECH LIMITED
    Inventors: Stephen Micheal Henry, Caroline Ann Oliver
  • Patent number: 10107826
    Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 23, 2018
    Assignee: Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Eisaku Yoshida, Ryotaro Chiba
  • Patent number: 10005834
    Abstract: The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: June 26, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jamie M. Orengo, Jeanne Allinne, Wen Fury, Yu Bai
  • Patent number: 9964538
    Abstract: Disclosed are sensitive methods for detecting a target substance in low concentrations. The method can include immobilizing a target substance to a solid phase; incubating the immobilized target substance with a reporter enzyme detection probe in solution under conditions for forming target: enzyme detection probe complexes; washing the solid phase to remove any unbound reporter enzyme detection probe; incubating the target: enzyme detection probe complex with a reporter enzyme detection probe substrate in substrate reaction solution to generate one or more ionizable products; and detecting one or more of the one or more ionizable products using mass spectrometry (MS).
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: May 8, 2018
    Assignee: YYZ Pharmatech, Inc.
    Inventors: John G. Marshall, Angelica Kirsten Florentinus
  • Patent number: 9895693
    Abstract: Devices, systems, methods, and kits are provided for performing separation, immobilization, blotting, and/or detection of analytes from biological samples. In some embodiments, the devices are constructed from two solid substrates with surfaces in contact. The devices include a plurality of channels formed from indentations in these surfaces. The indentations can be aligned with each other across the interface between the substrates, and realigned by shifting or sliding one substrate relative to the other. In some embodiments, the devices are constructed from three layers of a solid substrate. A separation channel in the middle layer of the device is first used for analyte separation. The middle layer can then be slid relative the top and/or bottom layer, thereby aligning the separation channel with a blotting membrane. Analytes can then be transferred to the membrane using electrodes in the top and bottom layers.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: February 20, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Clayton T. McKee, William Strong
  • Patent number: 9874558
    Abstract: An object of the present invention is to provide a method of measuring the amount of a compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin, which method is suitable for reduction of noise originating from impurities and determination of the exact amount of a target compound. The present invention provides a method of measuring the amount of a target compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin (including cases where a target compound-capturing substance other than an antibody is used as a ligand), the method containing adding a sugar chain compound which competes (crosses) with impurities contained in the biological sample in binding with the labeled lectin.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: January 23, 2018
    Assignee: KONICA MINOLT, INC.
    Inventors: Takeshi Isoda, Tomonori Kaneko
  • Patent number: 9827592
    Abstract: Provided is an ultrasonic probe that is capable of easily dissipating heat generated therein using porous carbon allotrope foams. The ultrasonic probe includes: a matching layer; a piezoelectric layer disposed on a bottom surface of the matching layer; and a backing layer disposed on a bottom surface of the piezoelectric layer and formed of porous carbon allotrope foams and backing materials.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: November 28, 2017
    Assignee: SAMSUNG MEDISON CO., LTD.
    Inventors: Won Hee Lee, Min Seon Seo, Bo Yun Kim
  • Patent number: 9827564
    Abstract: Fluidic systems and methods for analysis are provided. In some embodiments, systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: November 28, 2017
    Assignee: OPKO Diagnostics, LLC
    Inventors: David Steinmiller, Vincent Linder
  • Patent number: 9791436
    Abstract: A biosensor molecule comprises: a protease amino acid sequence; at least one sensor comprising at least one sensor amino acid sequence which is responsive to at least one target molecule; and an inhibitor of the protease activity of said protease amino acid sequence; wherein the biosensor is switchable from a protease active to a protease inactive state, or from a protease inactive to a protease active state when said sensor responds to said target molecule. The biosensor protease may be a protease of a virus such as a Potyvirus or a Flavivirus wherein the inhibitor is an autoinhibitory peptide derived from the virus. The biosensor may respond to the target molecule allosterically or may be cleaved by a target protease molecule.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 17, 2017
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Kirill Alexandrov, Viktor Stein, Matt Trau
  • Patent number: 9720003
    Abstract: The present invention relates to a method for measuring Troponin I in a sample comprising the steps of providing a sample, contacting the sample with a monoclonal anti-Troponin I antibody coupled to a magnetic label, contacting the sample with a polyclonal anti-Troponin I antibody coupled to a sensor surface and detecting the magnetic label on the sensor surface. The invention further relates to a device and a cartridge for measuring Troponin I in a sample.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: August 1, 2017
    Assignee: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Wendy Uyen Dittmer, Toon Hendrik Evers, Peggy De Kievit, Ricky Kamps, Joost Lambert Max Vissers, Michael Franciscus Wilhelmus Cornelis Martens, David Walterus Cornelis Dekkers
  • Patent number: 9650674
    Abstract: The present invention provides a composition comprising a fluorescent nucleic acid probe that can be cleaved by enzymatic and non-enzymatic means, and methods of using the same. Advantageously, the nucleic acid probe may be used to detect and quantify nucleic acid cleavage in vitro, in situ, ex vivo, and in vivo.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 16, 2017
    Assignee: BIOVENTURES, LLC
    Inventors: Alexei G. Basnakian, Yevgeniy Apostolov
  • Patent number: 9638687
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: May 2, 2017
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 9612236
    Abstract: The present invention is related to a method for detection of a biological target in an affinity assay, the method comprising the steps of providing a biological sample volume containing the biological target, adding a first capturing moiety to the biological sample volume comprising the biological target, wherein the first capturing moiety is adhered to a particle, concentration of the captured biological target into an elution volume that is smaller than the biological sample volume in step a), cleavage of the first capturing moiety or the biological target from the particle and direct or indirect detection and/or quantification of the biological target in a sandwich or competitive affinity assay format, wherein the biological target is associated with at least one capturing moiety, preferably at least two capturing moieties.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: April 4, 2017
    Assignee: Koninklijke Philips N.V.
    Inventors: Gwenola Sabatte, Menno Willem Jose Prins, Toon Hendrik Evers, Wilhelmina Maria Hardeman, Joukje Garrelina Orsel
  • Patent number: 9528998
    Abstract: Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 27, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Toru Yoshimura, Ryotaro Chiba
  • Patent number: 9498510
    Abstract: A polypeptide represented by SEQ ID NO: 1 and a method for treatment of a tumor and another disease associated with abnormal cell proliferation are described. The method includes administering a pharmaceutically-effective amount of the polypeptide to a patient in need thereof.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: November 22, 2016
    Assignee: WUHAN YICHENG BIOTECH. INC.
    Inventors: Junbo Hu, Xianmin Xia, Guihua Wang
  • Patent number: 9475870
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 25, 2016
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Patent number: 9429582
    Abstract: WW-binding protein 2 (WBP2) has been demonstrated in different studies to be a tyrosine kinase substrate, to activate ER?/PR transcription and to play a role in breast cancer. However, the role of WBP2 tyrosine phosphorylation in regulating ER function and breast cancer biology is unknown. Here, we established WBP2 as a tyrosine phosphorylation target of estrogen signaling via EGFR crosstalk. Using dominant negative, constitutively active mutants, RNAi and pharmacological studies, we demonstrated that phosphorylation of WBP2 at Tyr192 and Tyr231 could be regulated by c-Src and c-Yes kinases. We further showed that abrogating WBP2 phosphorylation impaired >60% of ER? reporter activity putatively by blocking nuclear entry of WBP2 and its interaction with ER?.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: August 30, 2016
    Assignee: National University of Singapore
    Inventor: Yoon Pin Lim
  • Patent number: 9377466
    Abstract: A molecular tool for use in a method of providing a molecule that is capable of binding a target molecule based on a set of polypeptides. A polypeptide having a sequence selected from SEQ ID NOs 1-32. The polypeptide may be used in a method of screening for a ligand-polypeptide conjugate capable of binding a target molecule for the ligand. A ligand-polypeptide conjugate, useful e.g. in therapy.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: June 28, 2016
    Assignee: Modpro AB
    Inventors: Lars Baltzer, Adam Slosarczyk, Jonas Bergquist, Anders Virtanen
  • Patent number: 9340820
    Abstract: Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: May 17, 2016
    Assignee: Queen's University of Belfast
    Inventors: Stella Lorraine Martin, Brian Walker
  • Patent number: 9303284
    Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP (SEQ ID NO: 9), and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP (SEQ ID NO: 10). In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: April 5, 2016
    Assignee: BioMadison, Inc.
    Inventors: Robert D. Fish, Min Dong
  • Patent number: 9284659
    Abstract: A method for crystallizing a substance dissolved in a solvent, including the following steps: introducing a solvent volume containing the substance into a chamber having a preset temperature, humidity, and gas composition, adding a predetermined volume of a precipitant to the solvent volume containing the substance, allowing the solvent to evaporate while simultaneously observing structural changes in the solvent volume containing the substance and the precipitant by means of dynamic light scattering, detecting weight changes and determining the molarities, making an association with the location in the phase diagram on the basis of the DLS measurement and the results of the molarity determination, allowing a predetermined number of crystal nuclei to form by adding solvent or adding precipitant, putting the solvent volume containing the substance and the precipitant into a metastable state by adding solvent and/or protein solution or by allowing the concentration of the dissolved substance to decrease by allo
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: March 15, 2016
    Assignee: Xtal Concepts GmbH
    Inventors: Christian Betzel, Rolf Hilgenfeld, Dierk Hilterhaus, Thomas Klupsch, Peter Muehlig, Karsten Dierks, Arne Meyer
  • Patent number: 9261443
    Abstract: Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: February 16, 2016
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
  • Patent number: 9249451
    Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a flexible peptide spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. The cleavage site sequence is a protease cleavage site, and the flexible spacer peptide is positioned and dimensioned to facilitate an electronic hop between the donor and acceptor label.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: February 2, 2016
    Assignee: BIOMADISON, INC.
    Inventors: Robert D. Fish, Min Dong
  • Patent number: 9201073
    Abstract: This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Usp14 (human), an endogenous inhibitor of the proteasome. The methods and compositions partially or completely reduce the inhibitory activity of Usp14 on a proteasome, thereby specifically enhancing the protein-degradation activity of the proteasome. The invention also provides methods of screening to identify inhibitors of Ubp6, Usp14, and/or both Ubp6 and Usp14.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: December 1, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Daniel J. Finley, John W. Hanna, Nathaniel A. Hathaway, Randall W. King, Byung-Hoon Lee
  • Patent number: 9193989
    Abstract: The present invention provides methods of identifying an agent that modulates PRPK, TPRKB, OSGEP, LAGE3 and its homologs, PRPK/TPRKB complex, and/or KEOPS complex. The present invention also provides compositions of such agents and methods of treating a disease, disorder, or condition associated with PRPK, TPRKB, OSGEP, LAGE3 and its homologs family (CT antigens), PRPK/TPRKB complex, and/or KEOPS complex using such an agent or composition.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: November 24, 2015
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Eun Sun Park, Henry E. Pelish, Astrid S. Clarke, Grace L. Williams, Maria Paola Castaldi, Alexander Arefolov, Jennifer E. Ring, Matthew D. Shair, Randall W. King
  • Patent number: 9182400
    Abstract: Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 10, 2015
    Assignee: PHADIA AB
    Inventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
  • Patent number: 9175038
    Abstract: Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: November 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Terrence R. Burke, Jr., Fa Liu, Kyung S. Lee, Jung-Eun Park
  • Patent number: 9116151
    Abstract: Disclosed is a method and associated device for the rapid identification of viable bacterial contaminants in food products. The method detects viable microbes by using a combined ATP-bioluminescence immunoassay. Escherichia coli O157:H7 and Salmonella enterica serovar Typhimurium were selected as target organisms in various matrices including ground beef homogenate, apple juice, milk, and phosphate-buffered saline. Specific antibodies were immobilized on the surface of well plates in which the sample matrices were incubated. The plates were washed, and the wells were incubated with BacTiter-Glo reagent in Mueller-Hinton II broth. Bioluminescent output was measured with a luminometer and signal-to-noise ratios were calculated. The LOD was not affected by the presence of non-target cells. A strong linear correlation was observed between the number of cells and luminescent output over 4 orders of magnitude.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: August 25, 2015
    Assignee: University of South Florida
    Inventors: Daniel V. Lim, Dawn M. Hunter
  • Patent number: 9116152
    Abstract: The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: August 25, 2015
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young Ki Paik, Keun Na
  • Patent number: 9079963
    Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: July 14, 2015
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Stefan Barth, Katharina Kolberg, Christiane Püttmann, Severin Schmies
  • Patent number: 9063089
    Abstract: Provided is an optical measuring apparatus including a light irradiating unit that irradiates a sample flowing through a flow path with light, a light detecting unit that detects optical information emitted from the sample due to light irradiation by the light irradiating unit, and a rate information adding unit that adds a predetermined display corresponding to a flow amount of the sample per unit time obtained from the optical information to a waveform data graph obtained from the optical information.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: June 23, 2015
    Assignee: SONY CORPORATION
    Inventor: Yosuke Muraki
  • Patent number: 9045794
    Abstract: The present invention features compositions and methods for the detection or measurement of oxalate in a sample. Such compositions include test devices that provide for the rapid and accurate detection of oxalate in a sample from a biological fluid. Advantageously, the compositions can be used to monitor the oxalate levels of a patient at a point of care (e.g., at the patient's home, clinic, physician's office, or other clinical setting).
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 2, 2015
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Ammon B. Peck, Cuong Q. Nguyen, Nigel G. John Richards
  • Publication number: 20150147762
    Abstract: Pancreatic cancer can be detected using a monoclonal antibody which binds to pancreatic RNase 1 when a site in pancreatic RNase 1 capable of being modified with an N-glycan chain is not linked to a glycan chain, but which does not bind to pancreatic RNase 1 when an N-glycan chain is linked to the site. Also provided is a monoclonal antibody which can bind to pancreatic RNase 1 simultaneously with the binding of the aforementioned antibody to pancreatic RNase 1, and determining the ratio of A to B using the antibodies, wherein A represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain, wherein an N-glycan chain is linked or not linked to the site; and B represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Applicant: TOSOH CORPORATION
    Inventor: Daisuke Nakatani
  • Publication number: 20150148411
    Abstract: Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Daniel Schramek, Elaine Fuchs
  • Publication number: 20150147309
    Abstract: The present invention relates to an allosteric non-inhibitory chaperone of the lysosomal acid alpha-glucosidase (GAA) for use in the treatment of a pathological condition characterized by a deficiency of the lysosomal acid alpha-glucosidase (GAA), to pharmaceutical composition thereof, to a method for increasing the activity of GAA in a subject and to a method for identifying an allosteric non-inhibitory chaperone for GAA.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Inventors: Giancarlo Parenti, Caterina Porto, Marco Moracci, Maria Carmina Ferrara, Beatrice Cobucci-Ponzano, Generoso Andria
  • Publication number: 20150148248
    Abstract: The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 28, 2015
    Inventors: Olivier Chinot, Emeline Tabouret
  • Publication number: 20150148661
    Abstract: A system for measuring analyte concentrations has porous-walled nanocontainers containing multiple magnetic nanoparticles, the magnetic nanoparticles coated with a selective binder that is analyte-responsive and binds a the analyte, an indicator substance releasable from the selective binder by the analyte, or an indicator substance cleavable by the analyte, apparatus for exposing the nanocontainers to a fluid potentially containing the analyte, and magnetic spectroscopy of Brownian motion sensing apparatus for detecting agglutination of the nanoparticles or binding of analyte to the nanoparticles.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 28, 2015
    Applicant: The Trustees of Dartmouth College
    Inventors: John B. Weaver, Barjor Gimi, Karl Griswold
  • Patent number: 9040249
    Abstract: Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: May 26, 2015
    Assignees: Beckman Coulter, Inc., University Health Network
    Inventors: David Hedley, Sue Chow, T. Vincent Shankey
  • Publication number: 20150141273
    Abstract: The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 21, 2015
    Inventors: Linda Janna Willemien Bosch, Meike De Wit, Beatriz Pinto Morais de Carvalho, Remond Johnnes Adriaan Fijneman, Gerrit Albert Meijer, Comelia Ramona Jimenez, Sander Rogier Piersma, Viet Thang Pham, Gideon Oudgenoeg
  • Publication number: 20150140573
    Abstract: The present invention relates to a method of detecting ?-(1?6)-glucosidase activity in a sample. The method is for example useful for determining the limit dextrinase activity in a sample. The method involves use of an oligosaccharide substrate of the formula X-(glucoside)n-*(glucoside)m-Z—Y, where X is a blocking group, -* is a ?-(1?6)-glucosidic linkage and Y is a detectable label. Upon cleavage of the ?-(1?6)-glucosidic linkage, the detectable label is released and thus the ?-(1?6)-glucosidase activity can be determined. The invention also relates to the oligosaccharide substrate per se.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 21, 2015
    Inventors: Marie Bøjstrup, Caspar Elo Christensen, Ole Hindsgaul
  • Publication number: 20150140124
    Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 21, 2015
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky